TIDMPRTC
PureTech Health PLC
27 February 2023
27 February 2023
PureTech Health plc
PureTech Founded Entity Sonde Health and Massachusetts General
Hospital Selected for National Institute on Aging Study to Examine
Use of Voice in Remote Detection and Monitoring of Mild Cognitive
Impairment Including Frontotemporal Disorders (FTD)
Project to leverage vocal biomarkers for cognitive assessment of
patients ages 55 and above in home environment
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, noted today
that its Founded Entity, Sonde Health , a health technology company
committed to bringing accessible health monitoring to everyone, in
conjunction with the Massachusetts General Hospital (MGH)
Frontotemporal Disorders (FTD) Unit, has been selected by the
Massachusetts Artificial Intelligence and Technology Center for
Connected Care in Aging & Alzheimer's Disease (MassAITC) to
lead a pilot study focused on leveraging vocal biomarkers for
remote detection and monitoring of mild cognitive impairment in the
home environment.
Funded by MassAITC and the National Institute on Aging (NIA), a
division of the U.S. National Institutes of Health (NIH), the
project is part of a $1.7 million grant to explore the use of
artificial intelligence and other advanced technologies for in-home
care. Specifically, it will evaluate the feasibility of obtaining
voice recordings of older individuals in the home environment that
can be used to longitudinally monitor speech and memory
functions.
"Nearly 90% of older adults wish to stay in their homes for as
long as possible. Digital technologies, and digital biomarkers in
particular, have great potential to support this shift," said David
Liu, CEO of Sonde Health. "By monitoring cognitive health from afar
through vocal biomarkers, Sonde's technology could help facilitate
this desire to 'age in place,' offering these patients the ability
to remain in a familiar environment without sacrificing quality
care."
The project will enroll 50 adults from the FTD Unit.
Participants will be ages 55 and above and represent a range of
cognitive function from normal cognition through subjective
cognitive decline, mild cognitive impairment (MCI), and mild
dementia. The longitudinal study will examine the potential of
Sonde's vocal biomarker platform to monitor and detect changes in
cognitive function for individuals at home.
The full text of the announcement from Sonde is below:
Sonde Health and MassGen Selected for MassAITC Pilot Study to
Examine Use of Voice in Remote Detection and Monitoring of Mild
Cognitive Impairment
Project to leverage vocal biomarkers for cognitive assessment of
patients ages 55 and above in home environment
BOSTON, MA - Feb. 27, 2023 - Sonde Health , a health technology
company committed to bringing accessible health monitoring to
everyone, in conjunction with the Massachusetts General Hospital
(MGH) Frontotemporal Disorders (FTD) Unit, has been selected by the
Massachusetts Artificial Intelligence and Technology Center for
Connected Care in Aging & Alzheimer's Disease (MassAITC) to
lead a pilot study focused on leveraging vocal biomarkers for
remote detection and monitoring of mild cognitive impairment in the
home environment.
Funded by MassAITC and the National Institute on Aging (NIA), a
division of the U.S. National Institutes of Health (NIH), the
project is part of a $1.7 million grant to explore the use of
artificial intelligence and other advanced technologies for in-home
care. Specifically, it will evaluate the feasibility of obtaining
voice recordings of older individuals in the home environment that
can be used to longitudinally monitor speech and memory
functions.
"Nearly 90% of older adults wish to stay in their homes for as
long as possible. Digital technologies, and digital biomarkers in
particular, have great potential to support this shift," said David
Liu, CEO of Sonde Health. "By monitoring cognitive health from afar
through vocal biomarkers, Sonde's technology could help facilitate
this desire to 'age in place,' offering these patients the ability
to remain in a familiar environment without sacrificing quality
care."
The project will enroll 50 adults from the FTD Unit.
Participants will be ages 55 and above and represent a range of
cognitive function from normal cognition through subjective
cognitive decline, mild cognitive impairment (MCI), and mild
dementia. The longitudinal study will examine the potential of
Sonde's vocal biomarker platform to monitor and detect changes in
cognitive function for individuals at home. Participants will
record 10-15 different voice samples and responses to cognitive
assessments both in the laboratory setting and from their personal
smartphones at home. Voice recordings will be analyzed for acoustic
features that correlate with mental status, which are expected to
provide insights into how vocal biomarkers can be used as an
effective tool for tracking cognitive health over time.
The pilot is part of MassAITC's larger mission to realize the
goal of aging at home through interdisciplinary research. It will
serve as an important reference data set to further test and
validate vocal biomarkers relevant to the detection or monitoring
of cognitive impairment. This study builds on several current Sonde
projects focused on testing cognitive biomarkers, including a
multi-year strategic partnership with GN Group to research and
develop commercial vocal biomarkers for MCI.
"As the population of older adults continues to grow, there is a
critical need for remote monitoring technologies that can detect
cognitive impairment early and accurately," said Deepak Ganesan ,
Director of the MassAITC. "By supporting a study that combines
Sonde Health's vocal biomarker technology and Massachusetts General
Hospital's expertise in clinical dementia research, we believe
we're one step closer to developing the tools and resources needed
to elevate aging-in-place care models."
"With this pilot study, we are excited to partner with Sonde
Health to contribute new insights into how voice-based remote
monitoring of cognitive function for older adults will potentially
augment specialized clinical evaluations," said Brad Dickerson, MD,
Director of the MGH Frontotemporal Disorders Unit and Professor of
Neurology at Harvard Medical School.
Research reported in this press release was supported by the NIA
of the NIH under award number P30AG073107.
About Sonde Health
Sonde Health is a leader in voice-based health monitoring. Sonde
serves top health companies, providers, pharma, and device OEMs
through its vocal biomarker platform. Leveraging a best-in-class
voice data set with over 1.2 million samples from 85,000+
individuals on four continents, Sonde uses advanced audio signal
processing, speech science, and AI/machine learning to sense and
analyze subtle vocal changes due to changes in a person's
physiology to provide key insights into health and
well-being.www.sondehealth.com
About Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original
and largest teaching hospital of Harvard Medical School. The Mass
General Research Institute conducts the largest hospital-based
research program in the nation, with annual research operations of
more than $1 billion and comprises more than 9,500 researchers
working across more than 30 institutes, centers and departments. In
August 2021, Mass General was named #5 in the U.S. News & World
Report list of "America's Best Hospitals." MGH is a founding member
of the Mass General Brigham healthcare system.
www.partnersi.co.kr/eng/
About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the
treatment paradigm for devastating diseases. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two (Plenity(R) and EndeavorRx(R)) that have
received both U.S. FDA clearance and European marketing
authorization and a third (KarXT) that will soon be filed for FDA
approval, as of the most recent update by the Company. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation those
related to the potential of Sonde's vocal biomarker platform to
monitor and detect changes in cognitive function for individuals at
home, current Sonde projects focused on testing cognitive
biomarkers, including the study with MGH, and Sonde's future
prospects, development plans, and strategies. The forward-looking
statements are based on current expectations and are subject to
known and unknown risks, uncertainties and other important factors
that could cause actual results, performance and achievements to
differ materially from current expectations, including, but not
limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2021 filed with the SEC
and in our other regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the Company and the environment in
which it will operate in
the future. Each forward-looking statement speaks only as at the
date of this press release. Except as required by law and
regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National
Institutes of Health.
Contact:
PureTech
Public Relations
publicrelations@puretechhealth.com
Investor Relations
IR@puretechhealth.com
EU Media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
ben.atwell@FTIconsulting.com
U.S. Media
Nichole Sarkis
+1 774 278 8273
nichole@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEALAXAEKDEFA
(END) Dow Jones Newswires
February 27, 2023 09:09 ET (14:09 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024